HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDMA objects to extending Reye syndrome warning to nonaspirin salicylates.

This article was originally published in The Rose Sheet

Executive Summary

NDMA OBJECTS TO EXTENDING REYE SYNDROME WARNING TO NONASPIRIN SALICYLATES based on a lack of scientific evidence and the fact that they are widely used and irreplaceable. In a Feb. 28 letter to FDA, the Nonprescription Drug Manufacturers Association asserted that it does "not believe that extension of the Reye syndrome warning to nonaspirin salicylates is warranted based on the lack of available evidence implicating nonaspirin salicylates used as excipients, or otherwise, as being associated with the development of Reye syndrome."
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS001444

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel